Provided by Tiger Trade Technology Pte. Ltd.

OCUMENSION-B

5.200
-0.085-1.61%
Volume:879.00K
Turnover:4.50M
Market Cap:4.24B
PE:-22.31
High:5.340
Open:5.340
Low:5.000
Close:5.285
52wk High:12.070
52wk Low:4.040
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:3.40
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.233
ROE:-4.26%
ROA:-2.48%
PB:0.99
PE(LYR):-22.31
PS:4.52

Loading ...

Revised title

Stock News
·
Apr 02

Trump's Pharmaceutical Tariff Deadline Approaches: Firms Without Pricing Agreements Face 100% Levies

Stock News
·
Apr 02

Baiyunshan Pharmaceutical Division Secures NMPA Approval for Calcitriol Soft Capsules

Stock News
·
Apr 01

OCUMENSION-B Shares Surge Over 16% Afternoon Following First Patient Enrollment in Phase III Dry Eye Treatment Trial

Stock News
·
Apr 01

Gushengtang appoints Boyu Capital partner Cao Yanling as non-executive director

Reuters
·
Apr 01

ASCLETIS-B Reports Annual Loss Attributable to Shareholders of 360 Million Yuan, Widening 19.6% Year-on-Year

Stock News
·
Mar 31

CMB International Maintains "Buy" on Sino Biopharm, Adjusts Target Price to HK$8.7

Stock News
·
Mar 31

OCUMENSION-B (01477) Announces First Patient Enrolled in OT-211 Phase III Clinical Trial

Stock News
·
Mar 30

Ocumension completes first patient enrollment in China Phase III trial of OT-211 dry eye drug

Reuters
·
Mar 30

Herbal Formula Pharmaceutical Faces Bribery Scandal Involving Core Product During Hong Kong IPO Push

Deep News
·
Mar 29

Rocket Pharmaceuticals Shares Surge as FDA Approves First Treatment for Fatal Pediatric Rare Disease

Deep News
·
Mar 27

Claims Process Ongoing for Pulishi Pharmaceutical Investors, Eligible Parties Can Still Join

Deep News
·
Mar 27

Novartis Acquires Excellergy for $2 Billion to Strengthen Food Allergy and Immune Disorder Portfolio

Stock News
·
Mar 27

Pharma Firm's IPO at Risk as Bribery Scandal Involving Flagship Product Emerges

Deep News
·
Mar 27

Distinct Family Control Characteristics Emerge as Relative's Firm Receives Hundreds of Millions in Promotion Fees

Deep News
·
Mar 27

OCUMENSION-B (01477) Proposes Appointment of Zhuang Beibei as Independent Non-Executive Director

Stock News
·
Mar 26

OCUMENSION-B Reports Annual Results: Net Loss Narrows 40.8% to 159 Million Yuan

Stock News
·
Mar 26

Ocumension FY2025 Revenue Jumps 92.7% to RMB804.40 million; Gross Margin 44.9% and Adjusted EBITDA Turns Positive

Bulletin Express
·
Mar 26

OCUMENSION-B to Replace Retiring Independent Director Anthony Wu with Audit Veteran Beibei Zhuang

Bulletin Express
·
Mar 26

Ocumension Therapeutics FY Revenue RMB 804.4 Million

THOMSON REUTERS
·
Mar 26